Rottapharm SpA - Product Pipeline Review - 2014

Published: Dec, 2014 | Pages: 52 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Rottapharm SpA - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Rottapharm SpA - Product Pipeline Review - 2014', provides an overview of the Rottapharm SpA's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Rottapharm SpA's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Rottapharm SpA including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Rottapharm SpA's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Rottapharm SpA's pipeline products

Reasons to buy

- Evaluate Rottapharm SpA's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Rottapharm SpA in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Rottapharm SpA's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Rottapharm SpA and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Rottapharm SpA
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Rottapharm SpA and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Rottapharm SpA Snapshot 6
Rottapharm SpA Overview 6
Key Information 6
Key Facts 6
Rottapharm SpA - Research and Development Overview 7
Key Therapeutic Areas 7
Rottapharm SpA - Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products - Monotherapy 12
Rottapharm SpA - Pipeline Products Glance 13
Rottapharm SpA - Late Stage Pipeline Products 13
Phase III Products/Combination Treatment Modalities 13
Rottapharm SpA - Clinical Stage Pipeline Products 14
Phase II Products/Combination Treatment Modalities 14
Rottapharm SpA - Early Stage Pipeline Products 15
Preclinical Products/Combination Treatment Modalities 15
Discovery Products/Combination Treatment Modalities 16
Rottapharm SpA - Drug Profiles 17
andolast 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
dexloxiglumide 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
CR-3294 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
CR-4056 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
itriglumide 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
neboglamine 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
CR-6086 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
CRB-0016 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
CRB-0017 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
CRB-0089 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
BRU-8392 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
CR-4174 Series 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
CR-4892 Series 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
CR-5259 Series 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
CR-5542 Series 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
CR-5772 Series 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
CR-5790 Series 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
CR-8357 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
CRB-0022 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
VA-964 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Rottapharm SpA - Pipeline Analysis 37
Rottapharm SpA - Pipeline Products by Target 37
Rottapharm SpA - Pipeline Products by Route of Administration 39
Rottapharm SpA - Pipeline Products by Molecule Type 40
Rottapharm SpA - Pipeline Products by Mechanism of Action 41
Rottapharm SpA - Recent Pipeline Updates 43
Rottapharm SpA - Dormant Projects 46
Rottapharm SpA - Discontinued Pipeline Products 47
Discontinued Pipeline Product Profiles 47
dexloxiglumide 47
Rottapharm SpA - Locations And Subsidiaries 48
Head Office 48
Other Locations & Subsidiaries 48
Appendix 51
Methodology 51
Coverage 51
Secondary Research 51
Primary Research 51
Expert Panel Validation 51
Contact Us 52
Disclaimer 52

List of Tables
Rottapharm SpA, Key Information 6
Rottapharm SpA, Key Facts 6
Rottapharm SpA - Pipeline by Indication, 2014 9
Rottapharm SpA - Pipeline by Stage of Development, 2014 11
Rottapharm SpA - Monotherapy Products in Pipeline, 2014 12
Rottapharm SpA - Phase III, 2014 13
Rottapharm SpA - Phase II, 2014 14
Rottapharm SpA - Preclinical, 2014 15
Rottapharm SpA - Discovery, 2014 16
Rottapharm SpA - Pipeline by Target, 2014 38
Rottapharm SpA - Pipeline by Route of Administration, 2014 39
Rottapharm SpA - Pipeline by Molecule Type, 2014 40
Rottapharm SpA - Pipeline Products by Mechanism of Action, 2014 42
Rottapharm SpA - Recent Pipeline Updates, 2014 43
Rottapharm SpA - Dormant Developmental Projects,2014 46
Rottapharm SpA - Discontinued Pipeline Products, 2014 47
Rottapharm SpA, Other Locations 48
Rottapharm SpA, Subsidiaries 49